Most of my research has involved costing or cost-effectiveness analyses to inform interventions for infectious diseases in the Asia-Pacific region. Some of these include mass drug administration for scabies, public health measures for COVID-19, molecular testing for malaria and arboviruses, and pneumococcal conjugate vaccines. I am mailny interested in improving methods in economic evaluation. I am also keen on assessing multicomponent interventions, conducting evaluations using real-world data, and creating user- friendly decision models.
Journal articles
-
Le TP, Conway E, Akpan E, Abell I, Abraham P, Baker CM, Campbell PT, Cromer D, Lydeamore MJ, McDonough Y, Mueller I, Ryan G, Walker C, Wang Y, Carvalho N, McVernon J. “Cost-effective boosting allocations in the post-Omicron era of COVID-19 management.” medRxiv 2022; 2023. doi:
10.1101/2023.11.14.23298536 -
Akpan E, Hossain SJ, Devine A, Braat S, Hasan MI, Tipu SMMU, Bhuiyan MSA, Hamadani JD, Biggs BA, Pasricha S-R, Carvalho N. “Cost-effectiveness of universal iron supplementation and iron-containing micronutrient powders for anemia among young children in rural Bangladesh.” Am J of Clin Nutr 2022; 116(5):123–140. doi:
10.1093/ajcn/nqac225
Working papers
-
Akpan E, Thean LJ, Baskota R, Mani J, Mow M, Sahukhan A, Kama M, Tuicakau M, Kado J, Romani L, Engelman D, Whitfeld M, Kaldor J, Steer A, and Carvalho N. “Costs of primary healthcare presentations and hospital admissions for scabies and related skin infections in Fiji, 2018-2019.” PLOS Global Public Health 2024; ##(#):##–##. doi:
10.########